July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
Dexamethasone Implant for Diabetic Macular Edema in Naïve Compared To Refractory Eyes –A 24 Month The International Retina Group Real-Life Multicenter Study - IRGRel-DEX Study
Author Affiliations & Notes
  • Catharina Busch
    Department of Ophthalmology, University Hospital Leipzig, Leipzig, Germany
  • Matias Iglicki
    Private Retina Office, University of Buenos Aires, Buenos Aires, Argentina
  • Dinah Zur
    Division of Ophthalmology, Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
  • Mali Okada
    Royal Victorian Eye and Ear Hospital, Melbourne, Victoria, Australia
  • Jay Chhablani
    L.V. Prasad Eye Institute, Banjara Hills, Hyderabad, India
  • Zafer Cebeci
    Department of Ophthalmology, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey
  • Samantha Fraser-Bell
    Department of Ophthalmology, Save Sight Institute, University of Sydney, Sydney, New South Wales, Australia
  • Voraporn Chaikitmongkol
    Retina Division, Department of Ophthalmology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand
  • Aude Couturier
    Service d'Ophtalmologie, Hôpital Lariboisière, Université Paris, Sorbonne Paris Cité, Paris, France
  • Ermete Giancipoli
    Department of Ophthalmology, Azienda Ospedaliero Universitaria Sassari, Sassari, Italy
  • Patricio Rodriguez
    Servicio de Retina, Centro Medico Zambrano Hellion, Tecnológico de Monterrey, San Pedro Garza García, Nuevo Leon, Mexico, Monterrey, Mexico
  • Matus Rehak
    Department of Ophthalmology, University Hospital Leipzig, Leipzig, Germany
  • Marco Lupidi
    Department of Biomedical and Surgical Sciences, Section of Ophthalmology , University of Perugia, Perugia, Italy
  • Adrian Tien-Chin Fung
    Department of Ophthalmology, Save Sight Institute, University of Sydney, Sydney, New South Wales, Australia
  • Michaella Goldstein
    Division of Ophthalmology, Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
  • Anat Loewenstein
    Division of Ophthalmology, Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
  • Footnotes
    Commercial Relationships   Catharina Busch, None; Matias Iglicki, None; Dinah Zur, None; Mali Okada, None; Jay Chhablani, None; Zafer Cebeci, None; Samantha Fraser-Bell, None; Voraporn Chaikitmongkol, None; Aude Couturier, None; Ermete Giancipoli, None; Patricio Rodriguez, None; Matus Rehak, None; Marco Lupidi, None; Adrian Fung, None; Michaella Goldstein, None; Anat Loewenstein, Allergan (C)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 1956. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Catharina Busch, Matias Iglicki, Dinah Zur, Mali Okada, Jay Chhablani, Zafer Cebeci, Samantha Fraser-Bell, Voraporn Chaikitmongkol, Aude Couturier, Ermete Giancipoli, Patricio Rodriguez, Matus Rehak, Marco Lupidi, Adrian Tien-Chin Fung, Michaella Goldstein, Anat Loewenstein; Dexamethasone Implant for Diabetic Macular Edema in Naïve Compared To Refractory Eyes –A 24 Month The International Retina Group Real-Life Multicenter Study - IRGRel-DEX Study. Invest. Ophthalmol. Vis. Sci. 2018;59(9):1956.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To investigate efficacy and safety of repeated dexamethasone (DEX) implants over 24 months in a real-life environment, in diabetic macular edema (DME) eyes that were treatment-naïve compared to eyes refractory to anti-VEGF treatment.

Methods : This multicenter international retrospective study assessed best corrected visual acuity (BCVA) and central subfield thickness (CST) of naïve and refractory eyes to anti-VEGF injections treated with DEX implants. Safety data (intraocular pressure rise and cataract surgery) were recorded.

Results : 130 eyes from 125 patients were included. Baseline BCVA and CST were similar for naïve and refractory eyes. Both groups improved significantly in vision after 24 months (p< 0.001). However, naïve eyes gained statistically significant more vision than refractory eyes (BCVA 0.36 ± 0.14 versus 0.47 ± 0.23 logMAR, p=0.005) and were more likely to gain ≥ 10 letters (OR 4.2, 95% CI 1.38 - 12.90, p=0.01). At 6, 12 and 24 months, CST was significantly decreased compared to baseline in both naïve and refractory eyes; however, CST was increased in refractory compared to naïve eyes (CST 279 ± 61 versus 313 ± 125, p=0.06).

Conclusions : Over a follow up of 24 months, vision improved in DME eyes following treatment with DEX implants, both in eyes that were treatment-naïve and eyes refractory to anti-VEGF treatment; however, improvement was greater in naïve eyes.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×